Plain-English translation of NCT06262594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can improve sleep quality in people who have epilepsy, particularly a type called sleep-related focal epilepsy. Many people with epilepsy struggle with poor sleep, which can make their condition harder to manage. Researchers want to see if this medication can help them sleep better.
Sleep problems are common in people with epilepsy and can affect their overall health and quality of life. There aren't many treatment options specifically designed for epilepsy-related sleep issues, so this trial is exploring whether this medication could be a helpful new option.
You likely qualify if…
You likely don't qualify if…
Participants will take either the active medication or a placebo pill by mouth each evening at bedtime. The study involves two treatment periods where participants may receive the placebo first and then the active medication, or vice versa. Throughout the trial, you'll visit the clinic for check-ups and possibly complete sleep logs or questionnaires to help researchers track any changes in your sleep.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Canada
Phase
Large-scale testing
Sponsor
University of Manitoba
Collaborators
Duke University
Enrollment target
~26 participants
Started
October 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marcus C Ng, MD, FRCPC
University of Manitoba
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.